Orserdu (elacestrant)
ESR1-mut HR+ breast CA ยท Oncology (Breast)
Ask about Orserdu
Tell us the medicine and your country. We reply within one business day. On WhatsApp we usually reply the same day.
About Orserdu
Orserdu (elacestrant) is a serd oral manufactured by Stemline/Menarini, used in the treatment of ESR1-mut HR+ breast CA. It received FDA approval in 2023 under the Traditional pathway.
Case active and ready to skip the regulatory walkthrough? Ask about a medicine or WhatsApp us.
Accessing Orserdu through Reserve Meds
We help patients in the Middle East, India, Pakistan, Africa, and other regions access Orserdu via established Named Patient Program (NPP) and personal-import pathways. Every order requires a prescription from a licensed physician in the destination country.
What we need from you
- A prescription from a licensed physician in your country of residence.
- A clinical justification from the prescribing physician (why Orserdu for this patient).
- Destination-country NPP or personal-import paperwork (we help prepare these).
- Patient consent for cross-border drug import under the applicable pathway.
Typical timeline
We give you a written timeline estimate for your case before you commit. Timing varies by destination country regulatory review speed and physician documentation turnaround.
Indication context
Orserdu is indicated for ESR1-mut HR+ breast CA. The condition falls within Oncology (Breast). For patients with this condition in countries where Orserdu is not yet registered, NPP access is typically the primary legal pathway for obtaining treatment.
About the manufacturer
Orserdu is manufactured by Stemline/Menarini. We source drug supply exclusively through a US-licensed pharmaceutical wholesale partner, ensuring every unit is authentic, serialized, and chain-of-custody documented.
International regulatory status
- United States: FDA approved (2023).
- EMA (EU): Approved.
- MHRA (UK): Approved.
- Other countries: Approval status varies. Reserve Meds coordinates access under each destination country's NPP pathway.
Start a request for Orserdu
If you or a family member needs Orserdu and it is not available in your country, submit a request. Our clinical team will review eligibility and reach out within one business day.
Orserdu, country access pages
Information on how patients in different countries access Orserdu through Named Patient Program pathways.
- Orserdu in United Arab Emirates, The UAE recognises a formal Named Patient / compassionate-use pathway via MOHAP and the Department of Health Abu Dhabi (DoH). Physicians apply on behalf of individual patients for drugs not registered in-country.
- Orserdu in Saudi Arabia, The Saudi Food and Drug Authority (SFDA) operates a Personal Import / Unregistered Medicine pathway for named patients, typically requiring physician justification and hospital ethics-committee review.
- Orserdu in India, India's CDSCO permits import of unapproved drugs under Rule 36 for personal use by patients with a prescription from a registered medical practitioner. Named Patient import is common for rare-disease indications.
- Orserdu in Kuwait, Kuwait's Ministry of Health operates a Personal Import pathway for specialty drugs not registered locally, typically through a hospital pharmacy with physician attestation.
- Orserdu in Qatar, Qatar's MoPH permits unregistered drug import under a named-patient pathway with physician and MoPH approval; Hamad Medical Corp frequently sponsors.
- Orserdu in Bahrain, Bahrain's NHRA accepts named-patient import requests for rare-disease and specialty drugs not registered locally.
Safety, interactions, and handling
Drug interactions: Before dispatch, our clinical team reviews every patient's full medication list against published FDA drug-interaction data. If a significant interaction is identified, we notify the prescribing physician and hold shipment until an alternative dose or timing is confirmed.
Contraindications: This medication is not appropriate for every patient. Refer to the US FDA label for full contraindication list. Patients with active infection, pregnancy, known hypersensitivity, or specific organ-system comorbidities may be excluded. Prescribing-physician judgement applies.
Cold chain and storage: Biologics, monoclonals, and cell/gene therapies require validated cold-chain shipping (2-8°C) with continuous temperature monitoring. On arrival we document temperature logs; out-of-spec shipments are flagged and replaced.
Adverse event reporting: Any adverse event should be reported to both the local national regulator and to Reserve Meds's pharmacovigilance team at pv@reservemeds.com. We forward serious events to the US manufacturer within 15 days per ICH E2D guidance.
Last medically reviewed: 2026-04-22 (see Trust & Compliance).
Access by country
Reserve Meds publishes a detailed country deep-dive for Orserdu in every market we coordinate. Each page below covers the destination-country regulatory pathway (named-patient framework), how quotes work, indicative timelines, physician-credential requirements, and cold-chain handling for the route into that country. Tap any country to read the full deep-dive.
Clinical trials and expanded access
On 17 October 2026 we searched ClinicalTrials.gov, the clinical study registry of the US National Library of Medicine, for studies that list elacestrant as an intervention. The search found studies that are recruiting or not yet recruiting. See the current list on ClinicalTrials.gov.
Whether a patient can join a trial or an expanded access program is decided by the study team or the manufacturer, together with the treating doctor. Reserve Meds does not run trials or supply investigational medicines. We can help you and your doctor read a listing and understand the route.
Frequently asked questions
How can I get Orserdu if it is not approved or available in my country?
Reserve Meds coordinates US-sourced Orserdu for patients through a legal named-patient pathway, working with your treating doctor. Your treating physician provides the prescription and clinical justification; Reserve Meds prepares the named-patient documentation for your country and arranges DSCSA-compliant US sourcing and delivery to your physician or hospital pharmacy.
Can I access Orserdu through a named-patient import?
Often, yes. Named-patient access (sometimes called personal import) is the legal route we use for FDA-approved medicines such as Orserdu. It is different from compassionate use, which covers investigational medicines through the manufacturer's own program; we do not supply investigational medicines. Eligibility and paperwork depend on the regulator in your country, and Reserve Meds maps the specific pathway for each market it coordinates.
Do I need a prescription to access Orserdu through Reserve Meds?
Yes. Reserve Meds is not a pharmacy and does not prescribe. A valid prescription and clinical justification from your treating physician are required, and all clinical decisions remain with your physician.
How does Reserve Meds deliver Orserdu to a patient?
Medicines are supplied through a US-licensed pharmaceutical wholesale partner, and Reserve Meds coordinates delivery of Orserdu to your treating physician or hospital pharmacy, with appropriate handling for the product.
How long does it take, and what does Orserdu cost through Reserve Meds?
After a short intake, the clinical team responds within one business day with case-specific feasibility, an indicative timeline, and a formal written quote. Cost depends on the destination, the prescribed regimen, and the duration of therapy, and is confirmed in writing before anything proceeds.
How do I start a request for Orserdu?
Submit a 60-second intake through the Reserve Meds patient portal, or message our team on WhatsApp. We reply within one business day. On WhatsApp we usually reply the same day.